psalexa
logo

Acute coronary syndrome Therapeutics Pipeline Analysis

Acute coronary syndrome Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Delivery : 1-2 Working Days
Report Code: LS11000
Available Format:

The Acute coronary syndrome pipeline therapeutics pipeline is expected to increase on account of increasing population, which are at risk of severe cardiovascular disease. High blood pressure, uncontrollable blood sugar level, hypercholesterolemia, smoking are the main causes of developing acute coronary syndrome. Sometimes, stroke, emotional trauma also make a platform for emerging abnormalities in cardiovascular system. Amendments in lifestyle, routine and habit makes a big difference for increasing continuum of cardiovascular disease. Cumulative growth of pipeline is expected to grow as long as the arena of morbidities due to cardiovascular disease is occurring. In 2009, around 18% of men and 23% of women in United States were at risk of myocardial infarction, accordingly American Heart Association. Increasing the hospital therapy cost also a floating factor for expanding pipeline growth of acute coronary syndrome because it is a make-up of many diseases like myocardial ischemia, unstable angina, myocardial infarction etc.

The acute coronary syndrome is a collection of symptoms associated with myocardial ischemia, non—ST-segment elevation myocardial infarction, unstable angina and ST-segment elevation myocardial infarction. The diagnosis of non—ST-segment elevation myocardial infarction can be complete when ischemia become very severe to cause myocardial damage which leads to release of biomarkers of myocardial necrosis. Atherosclerosis can also occur in severe condition and plaque formation always progresses inexorably all over the person’s lifetime. The risk factors like smoking, diabetes, hypercholesterolemia and hypertension usually harm the blood vessels and which can give consequence such as, endothelial dysfunction.

In December 2014, Novartis AG is conducting clinical trials for estimation of safety and efficacy of everolimus drug in Infarct Size, Left Ventricular Remodeling and Inflammation in Patients with Acute ST-Elevation Myocardial Infarction. This study evaluation in Phase II clinical development. In January 2016, CorMatrix Cardiovascular, Inc.started a trial for evaluation of CorMatrix-ECM in cardiac infarct repair patients. This device Epicardial Infarct Repair with CorMatrix-ECM is in Phase I clinical study. In April 2013, AstraZeneca Plc is conducting clinical trial, double-blind study for comparison of ticagrelor with aspirin for prevention of vascular events in patients who are undergoing coronary artery bypass graft operation. This study of comparison of ticagrelor with aspirin is in Phase III. In March 2015, SIS Medical AG is conducting clinical trial for comparison of BVS Absorb implantation with DEB Sequent Please inflation for treatment of in-stent-restenosis. This study is in Phase III clinical development. In August 2016, Asklepion Pharmaceuticals, LLC is conducting clinical trial for the drug L-citrulline to evaluate its safety and efficacy for sequalae of acute lung injury caused by cardiopulmonary bypass in pediatric patients, who are undergoing surgery for congenital heart defects. This trial is in Phase III clinical development.

In June 2015, Sun Pharmaceutical Industries Ltd. and AstraZeneca Pharma India Limited (AZPIL) have entered into a distribution services agreement in India for AstraZeneca’s brand “Axcer”, a new brand of ticagrelor, a drug used for the treatment of acute coronary syndrome (ACS). AZPIL already has a brand under the trademark “Brilinta”, for ticagrelor molecule, which was launched and marketed by AZPIL in India since 2012.

Some of the companies having a pipeline of acute coronary syndrome therapeutics include, Roche Molecular Systems, Inc, MedImmune, LLC, AstraZeneca Plc, SIS Medical AG, Asklepion Pharmaceuticals, LLC, Genentech, Inc., GlaxoSmithKline plc.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3250
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4000
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry